In an 18-month study examining the utility of the drug adalimumab in preventing uveitis (eye inflammation) from developing among children with juvenile idiopathic arthritis (JIA), the following data were obtained:

	Uveitis	No uveitis	Total
Placebo (index group)	17	13	30
Adalimumab (reference group)	14	46	60
Total	31	59	90

1. Calculate the cumulative incidence of disease frequency for each of the 2 groups.